Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Neuroendocrine Tumor

This section has been reviewed and approved by the Cancer.Net Editorial Board, 5/2013
Latest Research

ON THIS PAGE: You will read about the scientific research being done now to learn more about this type of tumor and how to treat it. To see other pages in this guide, use the colored boxes on the right side of your screen, or click “Next” at the bottom.

Doctors are working to learn more about neuroendocrine tumors, how to best treat them, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the diagnostic and treatment options best for you.

New chemotherapy and drug combinations. A study has shown that the drug octreotide (Sandostatin) can slow tumor growth in patients with a neuroendocrine tumor of the midgut (the lower part of the small intestine) that has spread. Drugs used in chemotherapy, such as fluorouracil, leucovorin (Wellcovorin), and oxaliplatin (Eloxatin), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Targeted therapy and combined treatments. Monoclonal antibodies are a type of targeted therapy that can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Bevacizumab (Avastin) is a type of monoclonal antibody. It is focused on stopping angiogenesis, which is the process of making new blood vessels. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapies is to “starve” the tumor. When combined with chemotherapy, it may kill more tumor cells than chemotherapy alone. Bevacizumab may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Another anti-angiogenic drug being studied for neuroendocrine tumors is sorafenib (Nexavar), which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

New types of treatment. Antineoplastons are made out of mostly peptides and amino acids from blood and urine that may stop or slow the growth of tumor cells, while leaving other cells unaffected.

Supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current neuroendocrine tumor treatments in order to improve patients’ comfort and quality of life.

Looking for More about the Latest Research?

If you would like additional information about the latest areas of research regarding neuroendocrine tumors, explore these related items that will take you outside of this guide:

To continue reading this guide, choose “Next” (below, right) to see a section about coping with the side effects of this type of tumor or its treatment. Or, use the colored boxes located on the right side of your screen to visit any section.

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: